


Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515



SECRETARY OF THE S
05 AUG 11 AM 11:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Bristol-Myers Squibb Company			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 655 15th St., NW City Washington, DC State/Zip (or Country) 20005 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Richard Thompson	Telephone 202-783-8618	E-mail (optional)	5. Senate ID # 7053-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 7053

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) **OR** Year End (July 1-D

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobb

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$2,460,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate reporting method. See instructions for description of methods.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6013(e) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature *Richard L. Thompson* Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs]

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H.CON.RES.95, Establishing the congressional budget for the United States Government for fiscal year 2006, and setting forth appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2006, Lobbied against an amendment to remove language from the MMA prohibiting HHS from its negotiations for the drug benefit.

H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006, Lobbied to ensure safety of prescription drugs

H.R.3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, Lobbied for increased funding for RyanWhite program.

17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Agriculture
Department of Health & Human Services
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Pernie, Chris	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues
H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescription drugs.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Ryan, John	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs F

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.CON.RES.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection and effective treatment of viral hepatitis, and for other purposes, Lobbied for awareness of Hepatitis B

H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.

H.R.3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2006, Lobbied for increased funding for AIDS Drug Assistance Program.

H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs.

H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005, Lobbied to prevent importation of prescription drugs.

H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill.

S.1064, Stroke Treatment and Ongoing Prevention Act of 2005, Lobbied for passage of the bill.

17. House(s) of Congress and Federal agencies contacted Check if None
 House of Representatives
 Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Pernie, Chris	
Ryan, John	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs

Registrant Name: Bristol-Myers Squibb CompanyClient Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.753, Safe IMPORT Act of 2005 Safe Importation of Medical Products and Other Rx Therapies Act of 2005, Lobbied to prevent importation of prescription drugs.
16	Lobbying Issues	H.R.870, Pharmaceutical Research and Manufacturers Accountability Act (PhRMA Act of 2005, Lobbied to prevent provisions adverse to prescription approval process.
16	Lobbying Issues	S.109, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety prescription drugs.
16	Lobbying Issues	S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process.
16	Lobbying Issues	S.184, Safe IMPORT Act of 2005 Safe Importation of Medical Products and Other Rx Therapies Act of 2005, Lobbied to prevent importation of prescription drugs.
16	Lobbying Issues	S.334, Pharmaceutical Market Access and Drug Safety Act of 2005, Lobbied to ensure safety of prescription drugs.
16	Lobbying Issues	S.470, FACT Act Fair Access to Clinical Trials Act of 2005, Lobbied to improve patient access healthcare.
16	Lobbying Issues	S.852, FAIR Act of 2005 Fairness in Asbestos Injury Resolution Act of 2005, Ensure a fair system to resolve an asbestos claim.
16	Lobbying Issues	S.930, Food and Drug Administration Safety Act of 2005, Lobbied to ensure of prescription drugs.
16	Lobbying Issues	S.Res. 117, A resolution designating the week of May 9, 2005, as "National Hepatitis B Awareness Week", Lobbied for awareness of Hepatitis B
16	Lobbying Issues	Lobbied to allow new products for formulary inclusion while the current formulary contract is still in affect with regards to Abilify Access to Puerto Formulary.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse prescription drug approval process.

H.R.753, Safe IMPORT Act of 2005

Safe Importation of Medical Products and Other Rx Therapies Act of 2005, Lobbied to prevent unsafe imp prescription drugs.

H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005

PhRMA Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.

S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval pro

S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescrip approval process.

17. House(s) of Congress and Federal agencies contacted

Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Pernie, Chris	
Ryan, John	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs F

Registrant Name: Bristol-Myers Squibb CompanyClient Name: Self

Item	Description	Data
16	Lobbying Issues	S.184, Safe IMPORT Act of 2005 Safe Importation of Medical Products and Other Rx Therapies Act of 2005, Lobbied to prevent unsafe importation of prescription drugs.
16	Lobbying Issues	S.470, FACT Act Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions ad to prescription drug approval process.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied against signing a discharge petition t bill to a floor vote.

H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove the federally imposed cap on Puerto Rico for Medicaid funding.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Pernie, Chris	
Thompson, Richard	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs F

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

- H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit.**
- H.R.3, Transportation Equity Act: A Legacy for Users, Lobbied to prevent enactment of unnecessary new**
- H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to en**
- S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit.**
- S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage.**

17. House(s) of Congress and Federal agencies contacted

Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs P:

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TOR (one per page)

16. Specific Lobbying issues

H.R.516, Class Action Fairness Act of 2005, Lobbied to ensure passage of legislation to reduce abuses in the S.5, Class Action Fairness Act of 2005, Lobbied to ensure passage of legislation to reduce abuses in the legal

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 8/10/2005

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs P:

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

Pharmaceutical Research & Development

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

ADV, CAW, CSP, FOO, FOR, GOV, INS

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client


FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant or affiliated organization

Handwritten signature/initials

Signature  Date 01/10/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs P